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aCardiology, Swiss Cardiovascular Center Bern, University Hospital, Bern, Switzerland
bDepartment of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandIt is a pleasure to dedicate an issue of Progress in
Cardiovascular Diseases to high-altitude medicine, and we
gratefully thank the editors for giving us this opportunity.
The readers will discover that the frontiers of high-
altitude medicine are almost infinite and often extend to
low altitude. Why is this so? Progress in medicine is
intimately linked with the understanding of underlying
mechanisms of disease. At high altitude, the ambient
hypoxia triggers a series of physiologic responses that
affect principally the respiratory, cardiovascular, neuro-
endocrine, and renal systems with the goal of maintaining
adequate cellular oxygenation. At low altitude, the same
systems may be activated with the same goal. The trigger,
however, is not ambient hypoxia but hypoxemia that is
the consequence of an organ insufficiency, usually the
heart or the lung. Therefore, the ultimate goal of most
high-altitude researchers is not only to understand
physiologic (mal)adaptation to hypoxia for the benefit
of the millions exposing themselves to high altitude, but
to think beyond that, imagining how the knowledge
gained from field research at high altitude may be applied
to the much larger number of patients with hypoxia/
hypoxemia-associated diseases.
A recent example of research from our own group may
illustrate this state of mind. As detailed elsewhere in this
issue, high-altitude pulmonary edema (HAPE) offers a
unique model to study underlying mechanisms of pul-
monary edema in humans (see p 485 by Scherrer et al).Statement of conflict of interest: See page 450.
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doi:10.1016/j.pcad.2010.02.006Exaggerated hypoxic pulmonary hypertension is a hall-
mark of HAPE, and its triggering of alveolar fluid flooding
was thought to represent the main pathogenic mechanism.
Epidemiologic studies suggest that pathologic events
during the fetal/perinatal period may lead to systemic
vascular dysfunction later in life. In a study on fetal/
perinatal programming of pulmonary vascular dysfunction
performed at 4559 m, we found that healthy adults who
had transient lack of oxygen during the first days after
birth display exaggerated hypoxic pulmonary hyperten-
sion, similar in magnitude to that observed in HAPE-prone
subjects.1 Surprisingly, however, none of these young
individuals developed HAPE,2 indicating that exaggerated
pulmonary hypertension per se is not always sufficient to
trigger HAPE and that additional mechanisms play a role.
In subsequent studies, we showed that impaired alveolar
fluid clearance related to a defect of the transepithelial
sodium transport represents such an additional mechanism
because stimulation of this transport with a β-adrenergic
agonist prevents lung edema in HAPE-prone subjects.3
This high-altitude study demonstrated for the first time
that sodium-driven alveolar fluid clearance plays a
pathogenic role in pulmonary edema in humans and
may, therefore, represent an appropriate new target for its
therapy. Subsequent clinical studies then demonstrated
that β-adrenergic stimulation of this transport decreases
extravascular lung water in patients with acute lung injury4
and accelerates the resolution of pulmonary edema after
lung resection.5 Other examples on how high altitude may
represent a natural research laboratory for the study of
cardiovascular physiology and pathophysiology are pre-
sented by Scherrer et al (p 451).
As stated above, the primary goal of the physiologic
adaptation of the cardiovascular system and the lungs to
acute high-altitude exposure is to ensure maximal449
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organ tissues despite the
ambient lack of oxygen.
These different, early
and late, cardiovascularresponses to hypoxia, as well as their limitations, are
reviewed in detail by Naeije (p 456).
There are 3 syndromes of maladaptation to acute high-
altitude exposure, also called high-altitude illnesses: acute
mountain sickness, high-altitude cerebral edema, and
HAPE. The pathophysiology, prevention, and treatment
of the very frequent but usually benign syndrome of acute
mountain sickness and the fortunately much less frequent
high-altitude cerebral edema are summarized in a
comprehensive review by Imray and colleagues (p 467).
The new insight in the pathogenesis of HAPE provided
by Scherrer et al (p 485) is very exciting and, in many
ways, offers new ideas and concepts that could be tested
and translated into clinical medicine.
The in-depth review of Sartori et al (p 493) complements
the previous article by focusing on new physiologic and
pathologic concepts of lung fluid movements under hypoxic
conditions and their potential role in clinical practice.
High-altitude pulmonary edema is a life-threatening
problem, and physicians need to know how to advise
individuals planning high-altitude activities. The article by
Maggiorini et al (p 500) provides this up-to-date information
on how to treat and prevent this important disease.
Because of the development of modern transportation
systems, ascent to high altitude has become very easy.
Therefore, not only mountaineers, but ever-increasing
numbers of patients with cardiovascular disease are
exposing themselves to high altitude; and counseling of
such patients has become very important. The extent of
the risk is not easily quantifiable and depends largely on
the altitude reached, the acclimatization status, and the
leisure time activity planned. Burtscher and Ponchia
provide up-to-date information regarding risk stratifica-
tion in cardiovascular patients (p 507). In a very
practically oriented companion article, Rimoldi et al
provide recommendations on how to assess and advise
cardiovascular patients planning high-altitude exposure
and activity (p 512).
Sometimes, a hypoxic environment is deliberately
sought. This is the case for endurance athletes who try to
naturally augment their oxygen transport capacity. Several
approaches on how to achieve this goal efficiently have
been advocated and debated. Should the athlete “live highand train low” or rather “live low and train high,” or is that
all old-fashioned? Vogt and Hoppeler bring together the
latest concepts on that topic (p 525).
High-altitude hypoxia is sometimes deliberately sought
and sometimes just the destiny, as for the dwellers
permanently living at high altitude in the Andes, in the
Himalayas, or in other mountainous regions around the
globe. What are the cardiovascular adaptation mechanisms
that have been developed by these high-altitude popula-
tions, particularly by the Bolivian Aymaras? How do they
differ from chronic adaptation mechanisms of white
people living at the same altitude? These (dis)similarities
and their possible positive or negative long-term con-
sequences on cardiopulmonary health are discussed by
Stuber et al (p 534).
Adaptation mechanisms to hypoxia can sometimes go
beyond their primary goal of maintaining adequate tissue
oxygenation. This is the case in chronic mountain
sickness, a major public health problem. Affected patients
develop, usually insidiously over time, excessive erythro-
cytosis, hypoxemia, and pulmonary hypertension that are
associated with a corollary of nonspecific symptoms
having a major negative impact on quality of life. The
cardiovascular consequences of chronic mountain sick-
ness are brightly explained by León-Velarde et al in the
last article of this special issue (p 540).Statement of Conflict of Interest
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